UPDATED 6:50 AM PT – Wednesday, November 18, 2020
Regeneron Pharmaceauticals is gearing up to begin mass manufacturing of its antibody coronavirus treatment, which was administered to President Trump after he tested positive for COVID-19.
On Tuesday, the pharmaceutical company announced it has successfully been able to produce large quantities of the treatment in preparation for when it’s approved by the U.S. Food and Drug Administration (FDA).
“I think we’re right on track and we recently announced that we’re right on track with meeting that commitment,” stated George Yancopoulos, President of Regeneron Pharmaceauticals Inc. “We’ve already produced more than the 50,000 doses.”
We and our partners have been working as hard as possible to manufacture our investigational #COVID19 antibodies, while ensuring we also deliver our approved and investigational medicines to patients who need them. For more about our team, visit: https://t.co/NlRFTovCYW
— Regeneron (@Regeneron) November 12, 2020
The company expects to begin production at the start of 2021 and hopes to produce 2 million doses by the end of the year.
“We’re on track, by January, to fulfill the entire allotment and beyond that, we’re scaling up further in-house,” Yancopoulos continued. “And, of course, we established this very important and productive partnership with Roche Genentech to significantly expand the global capacity.”
The antibody cocktail still needs to be approved by regulators, but Regeneron Pharmaceuticals said they have been in daily talks with the FDA to gain emergency use authorization.